MGMT and neoplasm: Although the study did not achieve the primary endpoint, single agent ONC201 showed signs of anti-tumor activity in this pilot study of recurrent glioblastoma patients that was enriched for several poor prognosis features: unmethylated MGMT, age >50, subtotal resections, and baseline corticosteroid use.